A
Amaury Daste
Researcher at University of Bordeaux
Publications - 70
Citations - 1451
Amaury Daste is an academic researcher from University of Bordeaux. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 11, co-authored 56 publications receiving 784 citations.
Papers
More filters
Journal ArticleDOI
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
Robert L. Ferris,Robert I. Haddad,Caroline Even,Makoto Tahara,M Dvorkin,Tudor-Eliade Ciuleanu,Paul Clement,Ricard Mesia,Svetlana I. Kutukova,L. Zholudeva,Amaury Daste,J. Caballero-Daroqui,Bhumsuk Keam,Ihor Vynnychenko,Cedrik Lafond,J. Shetty,Helen Mann,J. Fan,Sophie Wildsmith,Nassim Morsli,Jérôme Fayette,Lisa Licitra +21 more
TL;DR: Higher survival rates at 12 to 24 months and response rates demonstrate clinical activity for durvalumab, while treatment-related AEs (trAEs) were consistent with previous reports.
Journal ArticleDOI
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Lillian L. Siu,Caroline Even,Ricard Mesia,Éva Remenár,Amaury Daste,Jean Pierre Delord,Jürgen Krauss,Nabil F. Saba,Lisle Nabell,Neal Ready,Irene Brana,Nuria Kotecki,Dan P. Zandberg,Jill Gilbert,Hisham Mehanna,Marcelo Bonomi,Anthony Jarkowski,Anthony Jarkowski,Giovanni Melillo,Jon Armstrong,Sophie Wildsmith,Jérôme Fayette +21 more
TL;DR: In patients with R/M HNSCC and low or no PD-L1 tumor cell expression, all 3 regimens exhibited a manageable toxicity profile and Durvalumab and durvalumAB + tremelimumab resulted in clinical benefit, with minimal observed difference between the two.
Journal ArticleDOI
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study
Marie Kostine,Léa Rouxel,Thomas Barnetche,R. Veillon,Florent Martin,Caroline Dutriaux,Léa Dousset,Anne Pham-Ledard,Sorilla Prey,Marie Beylot-Barry,Amaury Daste,Marine Gross-Goupil,Julie Lallier,Alain Ravaud,Edouard Forcade,Bernard Bannwarth,Marie-Elise Truchetet,Christophe Richez,Nadia Mehsen,Thierry Schaeverbeke +19 more
TL;DR: Tumour response was significantly higher in patients who experienced rheumatic irAEs and their management is of major interest, since ICIs are used with increasing frequency.
Journal ArticleDOI
Immune checkpoint inhibitors and elderly people: A review
Amaury Daste,Charlotte Domblides,Marine Gross-Goupil,Camille Chakiba,Amandine Quivy,Valérie Cochin,Erwan de Mones,Nicolas Larmonier,Pierre Soubeyran,Alain Ravaud +9 more
TL;DR: The impact of ageing and immunosenescence on immune system functions is discussed, and the safety and efficacy of immune checkpoint inhibitors in elderly patients are assessed, principally from the data of pivotal clinical trials with subgroup analysis.
Journal ArticleDOI
Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Khalil Saleh,Amaury Daste,Nicolas Martin,Elvire Pons-Tostivint,Anne Auperin,Ruth Gabriela Herrera-Gómez,Neus Baste-Rotllan,François Bidault,Joël Guigay,Christophe Le Tourneau,Esma Saada-Bouzid,Caroline Even +11 more
TL;DR: In R/M SCCHN, the ORR to SCT was high (30%) suggesting that exposure to ICI may increase tumour sensitivity to chemotherapy, and the age at SCT, number of prior chemotherapy regimens, type of chemotherapy before ICI, best response to ICi, site of relapse and Eastern Cooperative Oncology Group at S CT were not associated with response to S CT on univariate analysis.